TABLE 2.

Costs in Study Period^a

	PSP Cohort	Non-PSP Cohort	P Valueb
Number of patients	1,199	1,187	–
Total costs (medical+ drug), $	35,741 ± 38,405 (27,484)	39,713 ± 50,072 (27,740)	0.030
Medical costs, $c
Overall	18,322 ± 36,792 (6,151)	23,679 ± 49,300 (7,295)	0.003
Emergency department	256 ± 1,379 (0)	299 ± 862 (0)	0.364
Inpatient	5,960 ± 25,144 (0)	10,297 ± 39,067 (0)	0.001
Physician	3,473 ± 3,849 (2,168)	3,776 ± 5,502 (2,224)	0.119
Outpatient	8,633 ± 20,096 (1,940)	9,307 ± 21,102 (2,191)	0.425
Disease-related medical costs, $c,d
Overall	8,001 ± 23,336 (1,530)	10,202 ± 29,857 (1,683)	0.045
Emergency department	40 ± 495 (0)	36 ± 272 (0)	0.793
Inpatient	3,925 ± 19,913 (0)	5,880 ± 26,236 (0)	0.041
Physician	1,228 ± 1,885 (823)	1,288 ± 2,471 (729)	0.503
Outpatient	2,808 ± 10,350 (0)	2,998 ± 9,066 (71)	0.634
Drug costs, $e
Overall	17,419 ± 12,726 (18,264)	16,034 ± 12,705 (15,642)	0.008
Disease-related (biologics)f	16,630 ± 12,292 (17,680)	15,255 ± 12,265 (15,115)	0.006
Adalimumab	14,508 ± 11,433 (14,565)	13,264 ± 11,754 (11,345)	0.009
Other biologics	2,122 ± 6,896 (0)	1,992 ± 6,084 (0)	0.624
Other prescriptions	789 ± 1,752 (176)	778 ± 1,613 (181)	0.875

Source: Symphony Health Solutions claims database, 2008-2014.

Note: All data are expressed as mean ± SD (median).

^aCosts were evaluated over the 12-month period following the index date and were calculated using the service charge for medical claims and the primary plan payment for prescriptions.

^bPSP cohort versus non-PSP cohort.

^cExcludes biologic drug costs.

^dIncludes costs from medical claims with a corresponding diagnosis of an autoimmune disease indication for each patient.

^eIncludes biologic drugs covered by medical and pharmacy benefits, and any other prescription costs.

^fIncludes etanercept, anakinra, certolizumab pegol, golimumab, ustekinumab, abatacept, infliximab, and rituximab.

PSP = patient support program; SD = standard deviation.